Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Purchased: 600,000 ordinary shares.
- Purchase Price: 1,398.52 pence per share.
- Treasury Shares Held: 241,982,678 shares (post-transaction).
- Shares in Issue: 5,751,787,119 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through a buyback program. The company acquired 600,000 shares on January 17, 2007, which are now held in Treasury. This transaction updates the total number of shares in issue and the total voting rights available to shareholders.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory conformity with the Transparency Directive.
Investor Verification Checklist
- Verify the total number of shares in issue (5,751,787,119) for calculating ownership percentages under Financial Services Authority rules.
- Confirm the updated Treasury share count (241,982,678) for assessing potential future share buybacks or capital management strategies.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for revenue and earnings data.